NGNE EBITDA | Neurogene Inc.

Neurogene Inc. (NGNE) EBITDA

2026-06-30: Basis Reported; EBITDA -$35.86M*; Operating income -$36.67M; Depreciation and amortization $813.00K*.
2026-03-31: Basis Reported; EBITDA -$32.5M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$26.75M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$23M; Operating income (m); Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2017-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$35.86M*	-$36.67M	$813.00K*	(m)	(m)	$354.00K*	-$23.76M*	(m)	$25.47M	(m)	(m)
2026-03-31	Reported	-$32.5M	(m)	(m)	(m)	(m)	$281.00K	-$26.12M	(m)	$25.15M	(m)	(m)
2025-12-31	Reported	-$26.75M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$23M	(m)	(m)	(m)	(m)	$127.00K*	-$19.51M*	(m)	$17.24M	(m)	(m)
2025-06-30	Reported	-$25.28M	(m)	(m)	(m)	(m)	$148.00K*	-$19.46M*	(m)	$19.37M	(m)	(m)
2025-03-31	Reported	-$25.17M	(m)	(m)	(m)	(m)	$780.00K	-$20.77M	(m)	$17.76M	(m)	(m)
2024-12-31	Reported	-$20.73M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$21.38M	(m)	(m)	(m)	(m)	$167.00K*	-$15.56M*	(m)	$16.29M	(m)	(m)
2024-06-30	Reported	-$19.33M	(m)	(m)	(m)	-2090.16%	$460.00K*	-$15.89M*	(m)	$15.74M	(m)	(m)
2024-03-31	Reported	-$17.97M	(m)	(m)	(m)	(m)	$65.00K	-$21.65M	(m)	$13.54M	(m)	(m)
2023-12-31	Reported	-$13.92M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$14.42M	(m)	(m)	(m)	(m)	$82.00K*	-$11.57M*	(m)	$11.61M	(m)	(m)
2023-06-30	Reported	-$11.8M	(m)	(m)	(m)	(m)	$82.00K*	-$9.33M*	(m)	$10.32M	(m)	(m)
2023-03-31	Reported	-$12.22M	(m)	(m)	(m)	(m)	$29.00K	-$13.55M	(m)	$10.28M	(m)	(m)
2022-12-31	Reported	-$9.67M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$13.29M*	-$13.61M	$323.00K*	(m)	(m)	$322.00K*	-$9.29M*	(m)	$9.47M	(m)	(m)
2022-06-30	Reported	-$15.41M*	-$15.87M	$459.00K*	(m)	(m)	$232.00K*	-$11.29M*	(m)	$10.96M	(m)	(m)
2022-03-31	Reported	-$14.95M	(m)	(m)	(m)	(m)	$452.00K	-$14.09M	(m)	$10.70M	(m)	(m)
2021-12-31	Reported	-$14.78M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$15.10M*	-$15.45M	$356.00K*	(m)	(m)	$587.00K*	-$8.76M*	(m)	$9.90M	(m)	(m)
2021-06-30	Reported	-$14.81M*	-$15.12M	$313.00K*	(m)	(m)	$1.19M*	-$13.28M*	(m)	$9.82M	(m)	(m)
2021-03-31	Reported	-$14.7M	(m)	(m)	(m)	(m)	$1.09M	-$13.36M	(m)	$9.71M	(m)	(m)
2020-12-31	Reported	-$12.43M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$2.06M*	-$2.25M	$188.00K*	(m)	(m)	$487.00K*	-$112.00K*	(m)	$6.22M	(m)	(m)
2020-06-30	Reported	-$9.55M*	-$9.77M	$219.00K*	(m)	(m)	$972.00K*	-$8.79M*	(m)	$4.84M	(m)	(m)
2020-03-31	Reported	-$8.9M	(m)	(m)	(m)	(m)	$107.00K	-$6.44M	(m)	$5.50M	(m)	(m)
2019-12-31	Reported	-$8.2M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$59.42M*	-$59.52M	$98.00K*	(m)	(m)	(m)	-$6.53M*	(m)	(m)	(m)	(m)
2019-06-30	Reported	-$387.00K*	-$428.00K	$41.00K*	(m)	(m)	(m)	-$1.47M*	(m)	(m)	(m)	(m)
2019-03-31	Reported	(m)	(m)	$41.00K	(m)	(m)	(m)	-$2.76M	(m)	$104.00K	(m)	(m)
2018-09-30	Reported	(m)	-$15.20M	(m)	$0.00*	(m)	-$20.00K*	-$15.39M*	(m)	$10.71M	(m)	(m)
2018-06-30	Reported	(m)	$2.69M	(m)	$25.00M	(m)	$29.00K*	$9.18M*	(m)	$18.00M	(m)	(m)
2017-09-30	Reported	(m)	-$12.07M	(m)	(m)	(m)	$26.00K*	-$11.53M*	(m)	$8.46M	(m)	(m)
2017-06-30	Reported	(m)	-$13.99M	(m)	(m)	(m)	$344.00K*	-$10.30M*	(m)	$10.47M	(m)	(m)
2014-06-30	Reported	(m)	(m)	$71.94K	(m)	(m)	$64.61K	(m)	(m)	$4.55M	(m)	(m)
2014-03-31	Reported	(m)	(m)	$18.24K	(m)	(m)	$4.00K	(m)	(m)	$1.88M	(m)	(m)
2013-06-30	Reported	(m)	(m)	$15.59K	(m)	(m)	$2.54K	(m)	(m)	$1.25M	(m)	(m)
2013-03-31	Reported	(m)	(m)	$14.79K	(m)	(m)	$4.70K	(m)	(m)	$572.97K	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$100.29M	(m)	(m)	(m)	(m)	$1.18M	-$77.17M	(m)	$75.01M	(m)	$0.00
2024-12-31	Reported	-$79.41M	(m)	(m)	(m)	-8584.86%	$808.00K	-$70.60M	(m)	$60.92M	(m)	$0.00
2023-12-31	Reported	-$52.32M	(m)	(m)	(m)	(m)	$321.00K	-$51.42M	(m)	$44.39M	(m)	(m)
2022-12-31	Reported	-$53.32M	(m)	(m)	(m)	(m)	$2.23M	-$52.82M	(m)	$47.51M	(m)	(m)
2021-12-31	Reported	-$59.39M	(m)	(m)	(m)	(m)	$3.26M	-$47.56M	(m)	$39.16M	(m)	(m)
2020-12-31	Reported	-$32.94M	(m)	(m)	(m)	(m)	$2.22M	-$24.57M	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$70.62M	(m)	(m)	(m)	(m)	$879.00K	-$15.39M	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$32.34M	(m)	(m)	(m)	-129.34%	$49.00K	-$31.58M	(m)	$41.79M	(m)	(m)
2017-12-31	Reported	-$50.76M	(m)	(m)	(m)	(m)	$494.00K	-$44.72M	(m)	$36.27M	(m)	(m)
2016-12-31	Reported	(m)	-$37.65M	(m)	(m)	(m)	$713.00K	-$30.23M	(m)	$28.38M	(m)	$0.00
2014-12-31	Reported	(m)	(m)	$135.95K	(m)	(m)	$114.00K	(m)	(m)	$18.08M	(m)	$0.00
2013-12-31	Reported	(m)	(m)	$59.57K	(m)	(m)	$11.00K	(m)	(m)	$7.60M	(m)	-$5.00K
2012-12-31	Reported	(m)	(m)	$130.78K	(m)	(m)	$6.45K	(m)	(m)	$6.05M	(m)	$42.29K

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Shattuck Labs, Inc. (STTK)	United States	$0.634B	-13.30
IMPACT BIOMEDICAL INC. (IBO)	United States	$0.611B	66.47
Aquestive Therapeutics, Inc. (AQST)	United States	$0.606B	-6.67
CorMedix Inc. (CRMD)	United States	$0.605B	3.25
BlossomHill Therapeutics, Inc. (BLSM)	United States	$0.647B
CytomX Therapeutics, Inc. (CTMX)	United States	$0.598B	-10.25
Monopar Therapeutics (MNPR)	United States	$0.598B	-34.82
Altimmune, Inc. (ALT)	United States	$0.593B	-6.43
ZEVRA THERAPEUTICS, INC. (ZVRA)	United States	$0.668B	14.61
Phathom Pharmaceuticals, Inc. (PHAT)	United States	$0.572B	-8.76